Adelphi Values
Adelphi Values is recorded as a service provider in 16 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 16 of 16 trials · Latest update first
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
A two-stage double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult patients with lymphatic malformations associated with a PIK3CA mutation
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
Sponsor Meiragtx Ocular UK Limited
- Start (EU)
- Latest update
- Estimated end
A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- A March 2023 amendment increased planned enrollment from 450 to 470 participants and expanded the SRI population from approximately 20 to 40 participants to enable more comprehensive PK characterization.
- A March 2021 amendment required IgA nephropathy background medication in addition to ACE inhibitor/ARB therapy to be stable for at least 90 days before first dose and throughout the study, and changed the pharmacological steroid threshold from more than 10 mg/day to more than 7.5 mg/day prednisone/prednisolone equivalent.
- Change from baseline in eGFR at 9 months was promoted from exploratory to secondary and added to the interim testing strategy in April 2022, then removed from the testing strategy in March 2023 following FDA alignment.
These findings describe the trial, not the service provider’s performance or responsibility.
A multicenter, single-arm, open-label study to evaluate efficacy and safety of switching from anti-C5 antibody treatment to iptacopan treatment in study participants with aHUS
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients with Multiple Sclerosis
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide (ASO) against chronic Hepatitis B (CHB) followed by chronic Hepatitis B targeted immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA) therapy.
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema.
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3glomerulopathy
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Single-arm, Open-label Phase 4 Study of Nirogacestat in Adult Premenopausal Females with Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Sponsor Springworks Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
EPIK-P4: A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age with Moderate to Severe Endometriosis-related Pain
Sponsor Organon LLC
- Start (EU)
- Latest update
- Estimated end
A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Adelphi Values?
The 2026-10-09 snapshot links Adelphi Values to 16 distinct CTIS trials. Recorded services include CCI, Electronic data capture, interviews, Interviews, among 16 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Adelphi Values?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Immunology, Blood Disorders, Nephrology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Adelphi Values conducted?
The linked trials record locations in 19 countries, including Italy, Germany, Spain, France, Netherlands. These are trial locations, not confirmed office locations or countries where Adelphi Values delivered services.
What can this page tell me about Adelphi Values's trial experience?
Browse 16 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Adelphi Values. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Adelphi Values LLC
- Adelphi Values Limited